Bupropion/zonisamide
Combination drug
From Wikipedia, the free encyclopedia
Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]
Legal status
- Investigational
| |
| Combination of | |
|---|---|
| Bupropion | Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist |
| Zonisamide | Sulfonamide anticonvulsant |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| (verify) | |
